This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OMED OncoMed Pharmaceuticals (OMED) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About OncoMed Pharmaceuticals Stock (NASDAQ:OMED) 30 days 90 days 365 days Advanced Chart Get OMED alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.89▼$0.8952-Week Range N/AVolume1,201 shsAverage Volume768,904 shsMarket Capitalization$34.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California. Read More Receive OMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OMED Stock News HeadlinesTenaya Therapeutics appoints new interim principal accounting officerFebruary 8, 2025 | msn.comIonis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, PredictionsJune 8, 2023 | benzinga.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 2 at 2:00 AM | Crypto Swap Profits (Ad)Bispecific Antibody Market Size | Statistics By 2031April 7, 2023 | marketwatch.com2023, Bispecific Antibody Market is thriving worldwide by 2029March 30, 2023 | marketwatch.com2023-2029 Cancer Stem Cell Market Size and Risks Factors Analysis | Survey Report by Absolute ReportsFebruary 28, 2023 | marketwatch.comForecast for 2028, Bispecific Antibody Market 2023, Global Industry Trends, Share, Size, Growth, DemandFebruary 27, 2023 | marketwatch.comBispecific Antibody Market : Top Key Players Data with Upcoming Opportunities and InnovationsFebruary 16, 2023 | marketwatch.comSee More Headlines OMED Stock Analysis - Frequently Asked Questions How were OncoMed Pharmaceuticals' earnings last quarter? OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) released its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to analyst estimates of $7.97 million. OncoMed Pharmaceuticals had a negative net margin of 18.24% and a negative trailing twelve-month return on equity of 13.14%. What other stocks do shareholders of OncoMed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that OncoMed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), Bristol Myers Squibb (BMY), Nightstar Therapeutics (NITE), GW Pharmaceuticals (GWPH), Celldex Therapeutics (CLDX) and Clovis Oncology (CLVS). Company Calendar Last Earnings11/01/2018Today7/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OMED CIK1302573 Webwww.oncomed.com Phone650-995-8200FaxN/AEmployees22Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.10 million Net Margins-18.24% Pretax MarginN/A Return on Equity-13.14% Return on Assets-7.73% Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio5.04 Sales & Book Value Annual Sales$44.42 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / BookN/AMiscellaneous Outstanding Shares38,690,000Free FloatN/AMarket Cap$34.43 million OptionableOptionable Beta1.86 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:OMED) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoMed Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.